Tofacitinib, a drug used to treat arthritis and ulcerative colitis, may increase the risk of heart-related problems and cancer compared to tumor necrosis factor inhibitors (TNFis), according to an alert from the FDA. The news comes following the results of a safety trial, which was mandated by the FDA, and of which the results were announced last week by Pfizer (Xeljans is Pfizer’s brand name of tofacitinib).#cardiotwitter